Drug Trial Radar · NCT05437510
Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life
Last checked: Nov 20, 2026Latest source record: Oct 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,057
Actual
Start
Aug 8, 2022
Primary completion
Mar 27, 2024
Study completion Apr 9, 2025
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- AstraZeneca
- First posted
- Jun 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 days, up to 12 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine the efficacy and safety of a single intramuscular (IM) dose of nirsevimab, compared to no intervention, for the prevention of hospitalizations due to lower respiratory tract infection (LRTI) caused by confirmed RSV infection (henceforth referred to as RSV LRTI hospitalizations) in all infants under 12 months of age who were not eligible to receive palivizumab. The visit frequency was 1 in-person dosing/randomization visit, with monthly safety follow-up electronic contacts through the first 6 months post dosing/randomization for all participants. The study also included a 12-month (Day 366) follow-up telephone call. The D366 follow-up telephone call was the final follow-up telephone call for France, Germany and UK non-reconsented participants. The study included an 18-month (D546) and a 24-month (D731, final telephone call) follow-up telephone call for UK reconsented participants.
Conditions
- RSV Immunization
- Healthy Volunteer
Interventions
NirsevimabBiological
Pharmaceutical Form: Solution for Injection Route of Administration: Intramuscular
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) Hospitalization Through the Respiratory Syncytial Virus SeasonTime frame: From dosing/randomization (Day 1) up to approximately 7 months
Locations
240 sites in 3 countries. Site status is shown where the registry gives one.
Investigational Site 2500041
Aix-en-Provence, France
Investigational Site 2500002
Amiens, France
Investigational Site Number: 2500014
Bordeaux, France
Investigational Site 2500007
Brest, France
Investigational Site Number: 2500038
Brest, France
Investigational Site Number: 2500045
Brest, France
Investigational Site Number: 2500019
Bron, France
Investigational Site Number: 2500043
Brumath, France
Investigational Site Number: 2500001
Caen, France
Investigational Site Number: 2500032
Chambéry, France
Investigational Site Number: 2500057
Clamart, France
Investigational Site Number: 2500065
Clamart, France
Investigational Site Number: 2500029
Combs-la-Ville, France
Investigational Site Number: 2500013
Corbeil-Essonnes, France
Investigational Site Number: 2500054
Creil, France
Investigational Site Number: 2500006
Créteil, France
Investigational Site Number: 2500039
Créteil, France
Investigational Site Number: 2500023
Dijon, France
Investigational Site Number: 2500069
Draguignan, France
Investigational Site 2500008
Essey-lès-Nancy, France
Investigational Site 2500030
Étampes, France
Investigational Site Number: 2500058
Frouard, France
Investigational Site Number: 2500064
Grasse, France
Investigational Site Number: 2500004
Grenoble, France
Investigational Site Number: 2500027
Héry-sur-Alby, France
Investigational Site Number: 2500060
Huningue, France
Investigational Site 2500059
La Garenne-Colombes, France
Investigational Site Number: 2500071
La Teste-de-Buch, France
Investigational Site Number: 2500034
Le Kremlin-Bicêtre, France
Investigational Site Number: 2500072
Libourne, France
Investigational Site 2500046
Lille, France
Investigational Site 2500005
Lille, France
Investigational Site Number: 2500012
Limoges, France
Investigational Site Number: 2500037
Longjumeau, France
Investigational Site 2500021
Maromme, France
Investigational Site Number: 2500003
Marseille, France
Investigational Site Number: 2500073
Marseille, France
Investigational Site Number: 2500068
Mont-de-Marsan, France
Investigational Site Number: 2500066
Mont-Saint-Aignan, France
Investigational Site Number: 2500067
Montpellier, France
Showing 40 of 240 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.